Although angiotensin-converting enzyme inhibitors (ACEi) and angiotensin II receptor blockers (ARBs) are commonly used to manage proteinuria in chronic kidney disease, their potential protective role against anti-VEGF-related proteinuria remains unclear. Here, ACE is linked to chronic kidney disease.